Skip to main content
. 2015 Nov 24;67(12):1739–1749. doi: 10.1002/acr.22645

Figure 2.

Figure 2

Proportion of patients achieving American College of Rheumatology criteria for 20% improvement responses over time through week 100. PE = primary end point; Pbo = placebo; Ust = ustekinumab.